Although we have met one technical milestone, the 20 day moving average above the 100 day MA; EYES 50 day MA is still well below the 200 day MA. Because of the continued insider buying, I believe the ORION patient studies are promising. ORION opens up a new huge well defined market. When a market is this well defined and EYES is the clear worldwide leader; this stock has the potential for exponential returns. With potential exponential returns corresponding risk is always present. If ORION results are mixed or ORION fails I believe it will be a long time before we see a breakout and most likely EYES will retrace and it is back to the drawing board for Second Sight. The converse will result in exponential returns. It is a tough decision. My portfolio is substantially over-weighted with EYES. Because of this, human nature drives a bullish bias, conscious or not! Always take that into account as related to my occasional posts.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM